 |
|
Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis
A Randomized Controlled Trial
Edward Abraham, MD;
Konrad Reinhart, MD;
Steven Opal, MD;
Ignace Demeyer, MD;
Christopher Doig, MD, MSc;
Angel López Rodriguez, MD;
Richard Beale, MD;
Petr Svoboda, MD, PhD;
Pierre Francois Laterre, MD;
Stuart Simon, MD;
Bruce Light, MD;
Herbert Spapen, MD;
Judy Stone, MD;
Allan Seibert, MD;
Claus Peckelsen, MD;
Cathy De Deyne, MD;
Russell Postier, MD;
Ville Pettilä, MD;
Antonio Artigas, MD;
Sandra R. Percell, PhD;
Vincent Shu, PhD;
Christian Zwingelstein, PharmD;
Jeffrey Tobias, MD;
Lona Poole, MD;
James C. Stolzenbach, PhD;
Abla A. Creasey, PhD; for the OPTIMIST Trial Study Group
JAMA. 2003;290:238-247.
Context The expression and release of tissue factor is a major trigger for the activation of coagulation in patients with sepsis. Tissue factor pathway inhibitor (TFPI) forms a complex with tissue factor and blood protease factors leading to inhibition of thrombin generation and fibrin formation.
Objectives To determine if administration of tifacogin (recombinant TFPI) provides mortality benefit in patients with severe sepsis and elevated international normalized ratio (INR) and to assess tifacogin safety in severe sepsis, including patients with low INR.
Design and Setting A randomized, double-blind, placebo-controlled, multicenter, phase 3 clinical trial conducted from March 21, 2000, through September 27, 2001, in 245 hospitals in 17 countries in North America, Europe, and Israel.
Patients The primary efficacy population consisted of 1754 patients ( 18 years) with severe sepsis and a high INR (1.2) randomly assigned to intravenous infusion of either tifacogin (0.025 mg/kg per hour for 96 hours, n = 880) or placebo (arginine citrate buffer, n = 874), and 201 patients with a low INR (<1.2) randomly assigned to receive the same dose of either tifacogin or placebo.
Main Outcome Measure All-cause 28-day mortality.
Results Overall mortality at 28 days in the tifacogin-treated group (n = 880) vs the placebo group (n = 874) for high INR was 34.2% vs 33.9%, respectively (P = .88, Pearson  2 test; P = .75, logistic regression model). None of the protocol-specified secondary end points differed between the tifacogin vs placebo groups. An analysis on the first 722 patients demonstrated a mortality rate of 38.9% for placebo vs 29.1% for tifacogin (P = .006, Pearson 2 test). Tifacogin significantly attenuated prothrombin fragment 1.2 and thrombin:antithrombin complex levels (P<.001, 2-sample t test) in patients with high and low INR. Overall mortality was lower in the tifacogin response in patients with low INR (12%; n = 83) vs placebo (22.9%; n = 118) (P = .051, Pearson 2 test; P = .03, logistic regression model). There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).
Conclusions Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR. Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.
Author Affiliations: Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver (Dr Abraham); Anaesthesia Intensivtherapie, Friedrich-Schiller-University Jena, Jena, Germany (Dr Reinhart); Infectious Disease Division, Brown Medical School, Providence, RI (Dr Opal); Intensive Care Department, Onze-Lieve-Vrouw Ziekenhuis, Aalst, Belgium (Dr Demeyer); Department of Critical Care, University of Calgary, Calgary, Alberta (Dr Doig); Intensive Care Unit, Hospital Regional Universitario Infanta Cristina, Badajoz, Spain (Dr Rodriguez); Intensive Care Research Office, St Thomas Hospital, London, England (Dr Beale); Research Centre for Traumatology and Surgery of Ministry of Health, Brno, Czech Republic (Dr Svoboda); Intensive Care Service, University Hospital St Luc, Brussels, Belgium (Dr Laterre); South East Research Associates at Wellstar Cobb Medical Center, Austell, Ga (Dr Simon); St Boniface Hospital, Winnipeg, Manitoba (Dr Light); Intensive Care Unit, University Hospital, Brussels, Belgium (Dr Spapen); Memorial Hospital, Cumberland, Md (Dr Stone); Mobile Diagnostic Center at Providence Park, Mobile, Ala (Dr Seibert); City Hospital Munich-Harlaching, Munich, Germany (Dr Peckelsen); Oost Limburg Hospital, Genk, Belgium (Dr De Deyne); Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City (Dr Postier); Helsinki University Central Hospital, Helsinki, Finland (Dr Pettilä); Hadassah Hebrew University Medical Center, Jerusalem, Israel (Dr Sprung); Corporació Sanitaria Parc Tauli, Sabadell, Spain (Dr Artigas); Chiron Corporation, Emeryville, Calif (Drs Percell, Zwingelstein, Tobias, Poole, and Creasey); and Pharmacia Corporation, Skokie, Ill (Drs Shu and Stolzenbach).
RELATED ARTICLE
Unraveling Severe Sepsis: Why Did OPTIMIST Fail and What's Next?
Derek C. Angus and Mark A. Crowther
JAMA. 2003;290(2):256-258.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
When Is a Negative Phase II Trial Truly Negative?
Rubenfeld and Abraham
Am. J. Respir. Crit. Care Med. 2008;178:554-555.
FULL TEXT
New Antithrombotic Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Weitz et al.
Chest 2008;133:234S-256S.
ABSTRACT
| FULL TEXT
Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity
Bastarache et al.
Am. J. Physiol. Lung Cell. Mol. Physiol. 2008;294:L874-L881.
ABSTRACT
| FULL TEXT
Role of extracellular superoxide in neutrophil activation: interactions between xanthine oxidase and TLR4 induce proinflammatory cytokine production
Lorne et al.
Am. J. Physiol. Cell Physiol. 2008;294:C985-C993.
ABSTRACT
| FULL TEXT
Inflammation, endothelium, and coagulation in sepsis
Schouten et al.
J. Leukoc. Biol. 2008;83:536-545.
ABSTRACT
| FULL TEXT
Sepsis: rethinking the approach to clinical research
Marshall
J. Leukoc. Biol. 2008;83:471-482.
ABSTRACT
| FULL TEXT
Sepsis: A Clinical Update
Ventetuolo and Levy
CJASN 2008;3:571-577.
FULL TEXT
Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin
Schuepbach et al.
Blood 2008;111:2667-2673.
ABSTRACT
| FULL TEXT
Hydrocortisone Therapy for Patients with Septic Shock
Sprung et al.
NEJM 2008;358:111-124.
ABSTRACT
| FULL TEXT
A Comparative Study of the Protein C Pathway in Septic and Nonseptic Patients with Organ Failure
Borgel et al.
Am. J. Respir. Crit. Care Med. 2007;176:878-885.
ABSTRACT
| FULL TEXT
Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C
Kerschen et al.
J. Exp. Med. 2007;204:2439-2448.
ABSTRACT
| FULL TEXT
Gene Expression Profiling Identifies C/EBP{delta} as a Candidate Regulator of Endotoxin-induced Disseminated Intravascular Coagulation
Slofstra et al.
Am. J. Respir. Crit. Care Med. 2007;176:602-609.
ABSTRACT
| FULL TEXT
Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation
Choi et al.
Eur Respir J 2007;30:423-428.
ABSTRACT
| FULL TEXT
M protein from Streptococcus pyogenes induces tissue factor expression and pro-coagulant activity in human monocytes
Pahlman et al.
Microbiology 2007;153:2458-2464.
ABSTRACT
| FULL TEXT
Tissue Factor Expression, Angiogenesis, and Thrombosis in Pancreatic Cancer
Khorana et al.
Clin. Cancer Res. 2007;13:2870-2875.
ABSTRACT
| FULL TEXT
Immunomodulatory Effects of Fosfomycin in Experimental Human Endotoxemia
Sauermann et al.
Antimicrob. Agents Chemother. 2007;51:1879-1881.
ABSTRACT
| FULL TEXT
The cytoprotective protein C pathway
Mosnier et al.
Blood 2007;109:3161-3172.
ABSTRACT
| FULL TEXT
Review: New anticoagulants: a story of promise and disappointment
Watson and Greaves
British Journal of Diabetes & Vascular Disease 2007;7:51-58.
ABSTRACT
Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia
Renckens et al.
Blood 2007;109:1593-1601.
ABSTRACT
| FULL TEXT
Immunomodulatory effects of fosfomycin in an endotoxin model in human blood
Zeitlinger et al.
J Antimicrob Chemother 2007;59:219-223.
ABSTRACT
| FULL TEXT
Management of Sepsis
Russell
NEJM 2006;355:1699-1713.
FULL TEXT
Obesity and sepsis.
Vachharajani and Vital
J Intensive Care Med 2006;21:287-295.
ABSTRACT
Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome.
Cepkova and Matthay
J Intensive Care Med 2006;21:119-143.
ABSTRACT
Frequency of Abnormal Biphasic aPTT Clot Waveforms in Patients with Underlying Disorders Associated with Disseminated Intravascular Coagulation
Matsumoto et al.
CLIN APPL THROMB HEMOST 2006;12:185-192.
ABSTRACT
Tissue Factor in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications
Steffel et al.
Circulation 2006;113:722-731.
ABSTRACT
| FULL TEXT
The Last 100 Years of Sepsis
Vincent and Abraham
Am. J. Respir. Crit. Care Med. 2006;173:256-263.
ABSTRACT
| FULL TEXT
From the Cover: Polyphosphate modulates blood coagulation and fibrinolysis
Smith et al.
Proc. Natl. Acad. Sci. USA 2006;103:903-908.
ABSTRACT
| FULL TEXT
Drotrecogin Alfa (Activated) in Severe Sepsis
Friedrich et al.
NEJM 2006;354:94-96.
FULL TEXT
Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure
Welty-Wolf et al.
Am. J. Physiol. Lung Cell. Mol. Physiol. 2006;290:L21-L31.
ABSTRACT
| FULL TEXT
Effects of Recombinant Human Activated Protein C in Human Models of Endotoxin Administration
Abraham
Proc Am Thorac Soc 2005;2:243-247.
ABSTRACT
| FULL TEXT
Disseminated Intravascular Coagulation in Sepsis
Zeerleder et al.
Chest 2005;128:2864-2875.
ABSTRACT
| FULL TEXT
Activated Protein C Mediates Novel Lung Endothelial Barrier Enhancement: ROLE OF SPHINGOSINE 1-PHOSPHATE RECEPTOR TRANSACTIVATION
Finigan et al.
J. Biol. Chem. 2005;280:17286-17293.
ABSTRACT
| FULL TEXT
Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1
Ahamed et al.
Blood 2005;105:2384-2391.
ABSTRACT
| FULL TEXT
New anticoagulants
Hirsh et al.
Blood 2005;105:453-463.
ABSTRACT
| FULL TEXT
The Future of Anticoagulation
Dobesh et al.
Journal of Pharmacy Practice 2004;17:370-384.
ABSTRACT
Activated protein C variants with normal cytoprotective but reduced anticoagulant activity
Mosnier et al.
Blood 2004;104:1740-1744.
ABSTRACT
| FULL TEXT
New Anticoagulant Drugs: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Weitz et al.
Chest 2004;126:265S-286S.
ABSTRACT
| FULL TEXT
Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium
Chen et al.
Blood 2004;104:1344-1349.
ABSTRACT
| FULL TEXT
Evidence-Based Medicine in the ICU: Important Advances and Limitations
Vincent
Chest 2004;126:592-600.
ABSTRACT
| FULL TEXT
Evidence-Based Management of Critically Ill Patients: Analysis and Implementation
Gropper
Anesth. Analg. 2004;99:566-572.
ABSTRACT
| FULL TEXT
Timing Is Everything
Higgins
Chest 2004;126:4-6.
FULL TEXT
Bidirectional Relation Between Inflammation and Coagulation
Levi et al.
Circulation 2004;109:2698-2704.
FULL TEXT
Extended Evaluation of Recombinant Human Activated Protein C United States Trial (ENHANCE US): A Single-Arm, Phase 3B, Multicenter Study of Drotrecogin Alfa (Activated) in Severe Sepsis
Bernard et al.
Chest 2004;125:2206-2216.
ABSTRACT
| FULL TEXT
Data Safety and Monitoring Boards
Slutsky and Lavery
NEJM 2004;350:1143-1147.
FULL TEXT
Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia
Pawlinski et al.
Blood 2004;103:1342-1347.
ABSTRACT
| FULL TEXT
Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia
Kerlin et al.
Blood 2003;102:3085-3092.
ABSTRACT
| FULL TEXT
Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia
Derhaschnig et al.
Blood 2003;102:2093-2098.
ABSTRACT
| FULL TEXT
Unraveling Severe Sepsis: Why Did OPTIMIST Fail and What's Next?
Angus and Crowther
JAMA 2003;290:256-258.
FULL TEXT
|
